Vesicare (solifenacin) / Astellas - LARVOL DELTA

New drug approaches: ADC, bispec. antibody (DKK 2026) - No abstract available

Head and Neck Cancer • Oncology • Solid Tumor

Mirabegron in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - P=N/A | N=312 | Not yet recruiting | Sponsor: University of Naples | Initiation date: Jan 2026 ➔ Apr 2026

Trial initiation date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Overactive Bladder • Retinal Disorders

Clinical Observation on the Efficacy of Urethral Dilation Combined with Bladder Instillation in the Treatment of Overactive Bladder in Female Patients (ChiCTR) - P=N/A | N=100 | Completed | Sponsor: The People's Hospital of Linxia; The People's Hospital of Linxia

New trial • Overactive Bladder

Atrial fibrillation signals associated with overactive bladder drugs across JADER and FAERS: disproportionality and time-to-onset analyses. (PubMed, Front Pharmacol) - "Consistent AF signals were identified for solifenacin succinate and mirabegron, whereas other agents did not meet the prespecified criteria. These findings are hypothesis-generating, given the limitations of SRSs, such as underreporting, missing dates, and unknown exposure-and they reflect reporting patterns rather than causal risk. They outline strata and early treatment periods that may warrant clinical attention and help prioritize pharmacovigilance and targeted hypothesis-driven evaluation in routine OAB care."

Journal • Atrial Fibrillation • Cardiovascular • Overactive Bladder

Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy (clinicaltrials.gov) - P=N/A | N=61 | Completed | Sponsor: Mackay Memorial Hospital

New trial • Overactive Bladder

Effects of Treatment and Weather Variables on Nocturnal Enuresis: Long-Term Analysis Using the Classification and Regression Trees Model. (PubMed, Cureus) - "Our findings suggest that effective long-term management of NE may require individualized treatment plans that account for clinical and weather-related variables. Among weather-related variables, consideration of seasonal and environmental factors may be especially important in managing NE."

Journal • Pediatrics • Urinary Incontinence

Efficacy and Safety of Mirabegron Versus Solifenacin in the Treatment of Overactive Bladder in Children: A Systematic Review and Meta-Analysis (EAU 2026) - No abstract available

Retrospective data • Review • Overactive Bladder

Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females (clinicaltrials.gov) - P=N/A | N=80 | Completed | Sponsor: Ain Shams University

New trial • Overactive Bladder

Mirabegron in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - P3 | N=312 | Not yet recruiting | Sponsor: University of Naples

New P3 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Overactive Bladder • Retinal Disorders

Case Report: Double Trouble: Solifenacin and Fluoxetine's Unexpected QT Prolongation Synergy (ASHP 2025) - No abstract available

Case report • Clinical

Peroneal electric transcutaneous neuromodulation versus solifenacin in the treatment of the overactive bladder wet. (PubMed, Cent European J Urol) - "Both treatments led to significant and similar improvements in all bladder diary variables, OAB V8 score, and QoL. The results of this secondary analysis confirm that peroneal eTNM® has significantly better safety profile and comparable efficacy versus solifenacin in the subgroup of incontinent OAB patients."

Journal • Overactive Bladder

Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (clinicaltrials.gov) - P=N/A | N=72 | Active, not recruiting | Sponsor: Anne Estrup Olesen | Recruiting ➔ Active, not recruiting

Enrollment closed • Overactive Bladder

Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker (clinicaltrials.gov) - P=N/A | N=180 | Completed | Sponsor: Xing Liu | Recruiting ➔ Completed

Biomarker • Trial completion • Overactive Bladder • Pediatrics

Green HPLC-Fluorescence Method for Tamsulosin and Solifenacin in Dosage Forms Optimized by Box-Behnken Design. (PubMed, Luminescence) - "The proposed method was the only method used to assess the combined tablets content uniformity. Two greenness evaluation tools, GAPI and AGREE, were used to assess the greenness of the proposed HPLC method and the results showed a remarkable compliance with the green chemistry principles."

Journal

Sertraline-Induced Urine Incontinence. (PubMed, Eur J Case Rep Intern Med) - "Sertraline can rarely cause urinary incontinence, with symptoms showing a dose-response relationship that improves after dose reduction.Recognition and management of this adverse effect (through dose adjustment, switching or adjunctive therapy) allows clinicians to maintain psychiatric remission while minimising distressing urinary symptoms."

Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry • Urinary Incontinence • Urology

Persistence of Anticholinergic Agents in Patients With Overactive Bladder: A Cohort Study From the French National Health Insurance Claim Database (SNDS) (ISPOR-EU 2025) - "Solifenacin was the most prescribed at initiation (41.4%), followed by fesoterodine (38.4%). This study reveals limited persistence with ACH in the management of OAB in France. Most patients discontinued after a single delivery and remained without OAB treatment after 1-year of follow-up. These results highlight the need for strategies addressing treatment optimization and maintaining treatment adherence."

Claims database • Clinical • Reimbursement • US reimbursement • Cardiovascular • Hypertension • Overactive Bladder

Evaluation of the Potential Inhibitory Effects of Medications for Detrusor Overactivity on Platelet-Activating Factor (PAF)-Induced Mechanical Activity in Guinea Pig Bladder Smooth Muscle. (PubMed, Biol Pharm Bull) - "Ten clinically used DO drugs-oxybutynin, tolterodine, fesoterodine, propiverine, propantheline, solifenacin, imidafenacin, flavoxate, urapidil, and clenbuterol-were tested at a concentration of 10 μM, exceeding typical therapeutic plasma levels. Furthermore, oxybutynin (10 μM) also decreased 60 mM KCl-induced contractions by a similar extent and nearly abolished acetylcholine (ACh, 10 μM)-induced contractions. These findings suggest that oxybutynin suppresses PAF-induced UBSM hyperactivity through a mechanism distinct from its anticholinergic effect, likely mediated by blockade of voltage-dependent Ca2+ channels (VDCCs)."

Journal • Overactive Bladder

Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. (PubMed, Pharmaceuticals (Basel)) - "We designed this study to assess persistence, adherence, and patient satisfaction with FDCs recently introduced to the Polish pharmaceutical market, which contain tamsulosin (an α1-adrenergic receptor antagonist) in combination with solifenacin (a muscarinic receptor antagonist) or dutasteride (a 5-α reductase inhibitor). 2. The use of FDCs increases short-term satisfaction and persistence with therapy, with a mild effect on adherence."

Journal • Benign Prostatic Hyperplasia

Overactive bladder medications and risk of emergency hospital admissions with delirium in adults without dementia: self-controlled case series. (PubMed, Age Ageing) - "We observed increased hospital admission rates with delirium for adults without dementia whilst prescribed OAB anticholinergics, but not whilst prescribed mirabegron. Delirium risk remained raised for longer for men and was greater in older men. Alternative management options for OAB in older people should be considered before prescribing anticholinergic medications."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Overactive Bladder

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (clinicaltrials.gov) - P3 | N=120 | Recruiting | Sponsor: Mansoura University

Monotherapy • New P3 trial • Urinary Incontinence

Long-term clinical efficacy and cognitive impact of medications for overactive bladder related to the central nervous system. (PubMed, Int Urol Nephrol) - "OAB medication efficacy was comparable across medication types, but tolerability varied significantly, with the dementia, PD and solifenacin groups showing higher discontinuation rates. Cognitive impairment significantly influenced treatment outcomes, underscoring the need for tailored therapeutic strategies and regular cognitive assessments to optimise treatment effectiveness and maintain quality of life in patients with CNS-related OAB."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Overactive Bladder • Parkinson's Disease

Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder - A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence. (PubMed, Urologia) - "When compared to solifenacin 5 mg monotherapy, combination therapy with solifenacin/mirabegron markedly improved OABSS, micturition frequency, and urgency. When compared to monotherapy, all combinations were well tolerated and showed no significant extra safety concerns."

HEOR • Journal • Monotherapy • Constipation • Gastroenterology • Gastrointestinal Disorder • Overactive Bladder

Comparative efficacy of solifenacin and tamsulosin in alleviating stent-related symptoms: A systematic review and meta-analysis. (PubMed, Narra J) - "No significant differences were found between tamsulosin and solifenacin in terms of QoL (MD: 0.12; 95%CI: -0.01-0.26; p=0.070) and VAS (MD: 0.25; 95%CI: -0.95-1.44; p=0.690). In conclusion, solifenacin was more effective than tamsulosin in reducing stent-related symptoms, and the combination of tamsulosin and solifenacin was superior to either monotherapy in alleviating stent-related symptoms."

Journal • Retrospective data • Review • Urology

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms (clinicaltrials.gov) - P3 | N=189 | Recruiting | Sponsor: Bir Hospital | Not yet recruiting ➔ Recruiting

Enrollment open

Novel spectrophotometric approaches for analysis of solifenacin and silodosin in pharmaceutical preparations, human plasma, and environmental water samples: assessment of the methods' greenness and practicality. (PubMed, Anal Bioanal Chem) - "Method greenness and practicality were critically evaluated using the GAPI, AGREE, and the recently introduced CACI tool, all confirming the exceptional eco-friendliness and economic viability of the approaches. Full compliance with ICH Q2(R2) guidelines further affirms their validity for routine quality control and environmental monitoring."

Journal • Overactive Bladder